Roche Holding | ROG - Equity Capital And Reserves


Roche Holding reported CHF33.8B in Equity Capital and Reserves for its fiscal semester ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Alcon AG USD 22.03B 52M Dec/2025
Almirall EUR 1.49B 24.03M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bayer EUR 25.95B 3.75B Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Fresenius EUR 18.62B 320M Sep/2025
Fresenius Medical Care EUR 249.82M 12.7B Dec/2025
Galapagos EUR 3.24B 788.91M Dec/2025
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
GRIFOLS EUR 5.29B 108.05M Dec/2025
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 46.13B 1.38B Dec/2025
Orion EUR 1.28B 265.4M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Philips EUR 10.58B 204M Sep/2025
Recordati EUR 1.93B 57.32M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
UCB EUR 10.87B 1.18B Dec/2025